Answers are grounded in this paper and cite their sources.
The antiglucocorticoid cortexolone competes with triamcinolone acetonide (TA) for binding to specific receptors in rat thymocytes, and prevents the inhibitory action of TA on 2-deoxy[14C]glucose uptake and on the uptake and incorporation of [3H]uridine in these cells. Different sedimentation profiles were noted for the active glucocorticoid-receptor complex and the hormone antagonist-receptor complex. Thymocytes incubated with [3H]TA at 0° or 37° and extracted with a high salt buffer (0.15 m KCl) yielded a single receptor complex sedimenting at ∼4 S. At 0° and extraction with a low salt buffer, most of the [3H]TA was associated with the 27,000 x g supernatant and complexes sedimenting at ∼3.5 S and ∼7 S were observed in a 5 to 20% sucrose gradient. At 37° and low salt extraction, the [3H]TA was bound to a 27,000 x g pellet (containing 98% cellular DNA) from which it could be extracted with high salt to yield a ∼4 S complex. In contrast, cortexolone yielded a single receptor complex, ∼3.5 S, at both 0° and 37° after extraction of thymocytes with either the low or high salt buffer. Moreover, if the 37° low salt pellet is re-extracted with the high salt buffer, additional [3H]TA-receptor complex could be isolated but this was not the case for the [3H]cortexolone-receptor complex. When the [3H]TA receptor enters the nucleus it is firmly bound to an intranuclear molecule, whereas the cortexolone-receptor when taken up by the nucleus does not bind to an acceptor molecule. It is concluded that the lack of activity of the cortexolone-receptor complex is the result of a conformational change which allows for its uptake by the nucleus but decreases its affinity for a nuclear acceptor site and therefore does not mediate a biological response.
No takes yet. Share an insight, caveat, or question.
Turnell et al. (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: